| Website | stemline.com |
| Category | BioTech |
| Phone | 212-831-1111 |
| info@stemline.com | |
| Employees | |
| Founded | 8/03 |
| Description | Targeting cancer at its root |
| TOTAL | $12.5M |
| FUNDING TOTAL | $12.5M |
| Series A, 4/08 Pequot Capital | $12.5M |
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial.
Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called “StemScreen®†which the Company has utilized to identify multiple compounds that target and impair cancer stem cells.
Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed therapeutics, diagnostics, and drug screening.
